Literature DB >> 2106908

Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate.

B Melegh1, J Kerner, V Jaszai, L L Bieber.   

Abstract

The fate of supplemental carnitine was studied in human subjects treated with drugs known to cause carnitine deficiency. Six children were treated with pivampicillin and equimolar L-carnitine for 7 days. On the last day of treatment, the plasma levels of total and free carnitine were decreased, but acylcarnitine levels were increased. A 12-fold increase in urinary excretion of acylcarnitines was found; it increased from 188.5 +/- 82.7 to 2218.4 +/- 484.1 mumole/day, and 84% was pivaloylcarnitine. Free carnitine excretion was reduced. Ten epileptic children on chronic valproate treatment received equimolar carnitine for a 2-week period. Plasma carnitine levels were elevated on the last day of treatment. A 3.4-fold increase in urinary acylcarnitines was found, but most of the excreted carnitines were free (64.5-fold increases). These data show that pivalate is readily converted to carnitine esters, in contrast to the limited conversion of valproate to acylcarnitines in humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106908     DOI: 10.1016/0885-4505(90)90005-l

Source DB:  PubMed          Journal:  Biochem Med Metab Biol        ISSN: 0885-4505


  7 in total

1.  Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid.

Authors:  Noboru Okamura; Shuichi Ohnishi; Hiroyuki Shimaoka; Ryo Norikura; Hiroshi Hasegawa
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

2.  Diagnosis of isovaleric acidaemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme.

Authors:  J E Abdenur; N A Chamoles; A E Guinle; A B Schenone; A N Fuertes
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

3.  Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores.

Authors:  M Nakashima; T Uematsu; T Oguma; T Yoshida; K Mizojiri; S Matsuno; S Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

4.  Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans.

Authors:  K Totsuka; K Shimizu; M Konishi; S Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

5.  Carnitine status and safety after administration of S-1108, a new oral cephem, to patients.

Authors:  K Shimizu; A Saito; J Shimada; M Ohmichi; Y Hiraga; T Inamatsu; K Shimada; M Tanimura; Y Fujita; T Nishikawa
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs.

Authors:  K Mizojiri; S Futaguchi; R Norikura; Y Katsuyama; T Nagasaki; T Yoshimori; M Nakanishi
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 7.  Mass Spectrometric Analysis of L-carnitine and its Esters: Potential Biomarkers of Disturbances in Carnitine Homeostasis.

Authors:  Judit Bene; Andras Szabo; Katalin Komlósi; Bela Melegh
Journal:  Curr Mol Med       Date:  2020       Impact factor: 2.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.